DSP 3025

Drug Profile

DSP 3025

Alternative Names: AZD-3025; AZD-8848; DSP-3025

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer AstraZeneca; Sumitomo Dainippon Pharma
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Immunomodulators; Toll-like receptor 7 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic asthma; Seasonal allergic rhinitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Sep 2014 Discontinued - Phase-I for Allergic asthma (In volunteers) in Japan (Intranasal)
  • 30 Sep 2014 Discontinued - Phase-I for Allergic asthma (In volunteers) in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top